Monday October 25, 4:36 pm ET
Data presented at the Annual Meeting of the Society for Neuroscience

WALTHAM, Mass., Oct. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) today reported preclinical data for RG2417 in validated rodent models of anxiety at the annual meeting of the Society for Neuroscience. The preclinical data indicate that RG2417 has anti-anxiety properties in the animal models and may have activity in anxiety disorders. RG2417 is a proprietary formulation of the nucleoside uridine that is currently in development for the treatment of neuropsychiatric disorders and neurodegenerative diseases. Repligen previously reported the results of a Phase 1 clinical trial of a prodrug of uridine in bipolar disorder and major depression in which administration of the drug appeared to be safe and provided early evidence of clinical effect of the drug.

to read on... http://biz.yahoo.com/prnews/041025/nem063_1.html